Quizartinib Linked to Better AML Survival
A retrospective U.S. study found patients receiving quizartinib with chemotherapy had higher one-year overall survival than those given midostaurin.
Updated on Nov. 19, 2026 in Cancer

A retrospective comparative study of 215 adults with newly diagnosed FLT3-ITD-positive acute myeloid leukemia found quizartinib plus chemotherapy was associated with improved overall survival versus midostaurin plus chemotherapy. The study, published November 4, 2026, in JAMA Network Open, drew on patients treated at 12 U.S. academic medical centers.
Why it matters
The findings suggest quizartinib may offer survival advantages in a group of patients with a historically difficult-to-treat form of leukemia. Because the study was retrospective and excluded clinical trial patients, the results are associational rather than proof of a causal benefit.
The retrospective cohort of 215 patients (88 on quizartinib, 127 on midostaurin) found 1-year event-free survival hazard ratio of 0.43 favoring quizartinib (95% CI, 0.25-0.74). Whether the advantage holds in randomized settings and among patients treated after 2023 remains unresolved, as that subgroup did not reach statistical significance.
The players
JAMA Network Open
An open-access, peer-reviewed medical journal published by the American Medical Association that disseminates research across clinical medicine and health policy.
The details
Researchers compared outcomes among adults receiving intensive chemotherapy combined with either quizartinib or midostaurin, excluding patients treated in clinical trials. Dose interruptions, reductions or discontinuations occurred in 25.2% of midostaurin patients versus 11.4% of quizartinib patients.
Timeline
2018 to 2025: Patients were enrolled at 12 U.S. academic medical centers.
November 4, 2026: The study was published online in JAMA Network Open.
Treatment Landscape
The study places quizartinib against midostaurin, the established FLT3 inhibitor used alongside intensive chemotherapy for FLT3-ITD-positive AML. It offers a real-world comparison of two targeted options that clinicians have been weighing for newly diagnosed patients.
Patients and families discussing FLT3-ITD-positive AML treatment options may find these retrospective results relevant to conversations with their oncologists. The study does not establish that switching therapies is appropriate, and treatment decisions depend on individual clinical factors.
The takeaway
Patients with newly diagnosed FLT3-ITD-positive AML should discuss all available targeted options with their care team. Results from observational studies like this one can guide those conversations but should be weighed alongside randomized evidence and individual health factors.
Further reading
Explore more research on Cancer treatments and survival outcomes.
More information
Read the full JAMA Network Open study on quizartinib versus midostaurin.
Source note: This article includes information reported by Cancer Therapy Advisor.






